These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Quantitative determination of plasma fibrinolytic activity in patients with ruptured intracranial aneurysms who are receiving epsilon-aminocaproic acid: relationship of possible complications of therapy to the degree of fibrinolytic inhibition. Burchiel KJ; Hoffman JM; Bakay RA Neurosurgery; 1984 Jan; 14(1):57-63. PubMed ID: 6537999 [TBL] [Abstract][Full Text] [Related]
4. Myopathy associated with epsilon-aminocaproic acid (EACA) therapy. Report of two cases. MacKay AR; Sang U H; Weinstein PR J Neurosurg; 1978 Oct; 49(4):597-601. PubMed ID: 690689 [TBL] [Abstract][Full Text] [Related]
5. An experimental study of the influence of antifibrinolytic therapy on post-subarachnoid-hemorrhagic cerebral vasospasm and hydrocephalus. Kenning JA; Heros RC; Dujovny M; Latchaw RE; Nelson D Surg Neurol; 1984 Feb; 21(2):159-64. PubMed ID: 6701753 [TBL] [Abstract][Full Text] [Related]
6. Cerebral complication of antifibrinolytic therapy in the treatment of ruptured intracranial aneurysm. Animal experiment and a review of literature. Yamaura A; Nakamura T; Makino H; Hagihara Y Eur Neurol; 1980; 19(2):77-84. PubMed ID: 6893025 [TBL] [Abstract][Full Text] [Related]
7. Recurrent subarachnoid hemorrhage associated with aminocaproic acid therapy and acute renal artery thrombosis. Case report. Tubbs RR; Benjamin SP; Dohn DE J Neurosurg; 1979 Jul; 51(1):94-7. PubMed ID: 448423 [TBL] [Abstract][Full Text] [Related]
8. Experimental epsilon-aminocaproic acid (EACA) administration in the presence of subarachnoid blood. Ewald T; Mahaley S; Goodrich J; Wilkinson R; Silver D J Neurosurg; 1971 Dec; 35(6):657-63. PubMed ID: 5171110 [No Abstract] [Full Text] [Related]
14. Reducing the risk of rebleeding before early aneurysm surgery: a possible role for antifibrinolytic therapy. Leipzig TJ; Redelman K; Horner TG J Neurosurg; 1997 Feb; 86(2):220-5. PubMed ID: 9010423 [TBL] [Abstract][Full Text] [Related]
15. Myonecrosis as a complication of the use of epsilon amino-caproic acid: a case report and review of the literature. Kane MJ; Silverman LR; Rand JH; Paciucci PA; Holland JF Am J Med; 1988 Dec; 85(6):861-3. PubMed ID: 3057905 [No Abstract] [Full Text] [Related]
16. Ventriculostomy for the treatment of acute hydrocephalus following subarachnoid hemorrhage. Kusske JA; Turner PT; Ojemann GA; Harris AB J Neurosurg; 1973 May; 38(5):591-5. PubMed ID: 4711632 [No Abstract] [Full Text] [Related]
17. Rhabdomyolysis during treatment with epsilon-aminocaproic acid. Britt CW; Light RR; Peters BH; Schochet SS Arch Neurol; 1980 Mar; 37(3):187-8. PubMed ID: 7356431 [TBL] [Abstract][Full Text] [Related]
18. Why may epsilon-aminocaproic acid (EACA) induce myopathy in man? Report of a case and literature review. Galassi G; Gibertoni M; Corradini L; Colombo A Ital J Neurol Sci; 1983 Dec; 4(4):489-92. PubMed ID: 6674249 [TBL] [Abstract][Full Text] [Related]
19. Epsilon-aminocaproic acid and recurrent subarachnoid hemorrhage: a clinical trial. Shucart WA; Hussain SK; Cooper PR J Neurosurg; 1980 Jul; 53(1):28-31. PubMed ID: 7411206 [TBL] [Abstract][Full Text] [Related]
20. Chronic hydrocephalus after aneurysmal subarachnoid space hemorrhage. Huo G; Tang MY; Feng QL; Zheng LP; Yang G Acta Neurochir Suppl; 2011; 110(Pt 2):189-92. PubMed ID: 21125470 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]